rewirebio.iobenchmarks
Source

Evaluation of cell-free DNA approaches for multi-cancer early detection

Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 · Peer-reviewed

DOI: 10.1016/j.ccell.2022.10.022

Developer study: most authors are GRAIL employees with equity in Illumina, and several are inventors on related GRAIL patent applications (Declaration of interests). All classifiers were built and run by GRAIL. Samples are from CCGA (NCT02889978) substudy 1.

What this source contributed

Records in this release that cite this source. A record can cite several sources.

Results

Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.

Model or configurationMetricValueDatasetEvaluation
Allelic imbalance classifier (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (training set, post hoc 98% specificity threshold)25% (22%–28%) percentCCGA substudy 1 training set (1,414 analysable participants)allelic imbalance on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
Allelic imbalance classifier (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (validation set, post hoc 98% specificity threshold)22% (18%–26%) percentCCGA substudy 1 validation set (847 analysable participants)allelic imbalance on CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity
Clinical risk-factor classifier (no cfDNA), CCGA substudy 1Sensitivity at 98% specificity (training set, post hoc 98% specificity threshold)2.7% (1.7%–4.1%) percentCCGA substudy 1 training set (1,414 analysable participants)clinical data on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
Clinical risk-factor classifier (no cfDNA), CCGA substudy 1Sensitivity at 98% specificity (validation set, post hoc 98% specificity threshold)2.6% (1.4%–4.5%) percentCCGA substudy 1 validation set (847 analysable participants)clinical data on CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity
Fragment endpoint classifier (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (training set, post hoc 98% specificity threshold)22% (19%–25%) percentCCGA substudy 1 training set (1,414 analysable participants)fragment endpoints on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
Fragment endpoint classifier (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (validation set, post hoc 98% specificity threshold)18% (15%–22%) percentCCGA substudy 1 validation set (847 analysable participants)fragment endpoints on CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity
Fragment length classifier (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (training set, post hoc 98% specificity threshold)28% (25%–32%) percentCCGA substudy 1 training set (1,414 analysable participants)fragment lengths on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
Fragment length classifier (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (validation set, post hoc 98% specificity threshold)29% (25%–34%) percentCCGA substudy 1 validation set (847 analysable participants)fragment lengths on CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity
Pan-feature classifier over all cfDNA classifier scores (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (validation set, post hoc 98% specificity threshold)36% (31%–40%) percentCCGA substudy 1 validation set (847 analysable participants)pan-feature on CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity
Somatic copy number classifier (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (training set, post hoc 98% specificity threshold)33% (29%–36%) percentCCGA substudy 1 training set (1,414 analysable participants)SCNA on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
Somatic copy number classifier (GRAIL prototype), CCGA substudy 1Accuracy (cancer signal origin among 127 jointly detected validation cancers)41% percentCCGA substudy 1 validation cancers detected by all three representative classifiers (127)SCNA on CCGA substudy 1 validation set: cancer signal origin accuracy among jointly detected cancers
Somatic copy number classifier (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (validation set, post hoc 98% specificity threshold)27% (23%–31%) percentCCGA substudy 1 validation set (847 analysable participants)SCNA on CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity
Somatic copy number classifier with matched white-blood-cell correction (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (training set, post hoc 98% specificity threshold)33% (30%–37%) percentCCGA substudy 1 training set (1,414 analysable participants)SCNA-WBC on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
Somatic copy number classifier with matched white-blood-cell correction (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (validation set, post hoc 98% specificity threshold)30% (26%–34%) percentCCGA substudy 1 validation set (847 analysable participants)SCNA-WBC on CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity
Small somatic variant classifier on a 507-gene panel (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (training set, post hoc 98% specificity threshold)19% (16%–22%) percentCCGA substudy 1 training set (1,414 analysable participants)SNV on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
Small somatic variant classifier on a 507-gene panel (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (validation set, post hoc 98% specificity threshold)16% (13%–20%) percentCCGA substudy 1 validation set (847 analysable participants)SNV on CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity
Small somatic variant classifier with matched white-blood-cell background removal (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (training set, post hoc 98% specificity threshold)36% (33%–39%) percentCCGA substudy 1 training set (1,414 analysable participants)SNV-WBC on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
Small somatic variant classifier with matched white-blood-cell background removal (GRAIL prototype), CCGA substudy 1Accuracy (cancer signal origin among 127 jointly detected validation cancers)35% percentCCGA substudy 1 validation cancers detected by all three representative classifiers (127)SNV-WBC on CCGA substudy 1 validation set: cancer signal origin accuracy among jointly detected cancers
Small somatic variant classifier with matched white-blood-cell background removal (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (validation set, post hoc 98% specificity threshold)33% (29%–38%) percentCCGA substudy 1 validation set (847 analysable participants)SNV-WBC on CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity
Whole-genome methylation classifier (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (training set, post hoc 98% specificity threshold)39% (36%–43%) percentCCGA substudy 1 training set (1,414 analysable participants)WG methylation on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
Whole-genome methylation classifier (GRAIL prototype), CCGA substudy 1Accuracy (cancer signal origin among 127 jointly detected validation cancers)75% percentCCGA substudy 1 validation cancers detected by all three representative classifiers (127)WG methylation on CCGA substudy 1 validation set: cancer signal origin accuracy among jointly detected cancers
Whole-genome methylation classifier (GRAIL prototype), CCGA substudy 1Sensitivity at 98% specificity (validation set, post hoc 98% specificity threshold)34% (30%–39%) percentCCGA substudy 1 validation set (847 analysable participants)WG methylation on CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity

Claims

Statements this source supports, each with where in the source it was checked.

  • Evidence summary: plasma ctDNA fragmentomics workflows: Summary Eight sources compare plasma cfDNA fragmentomic workflows on retrospective case-control cohorts. None is a prospective screening study and none measures clinical benefit. Cristiano et al. 2019, the DELFI developers, report 73% sensitivity (152 of 208 cancers) at a reported 98% specificity for DELFI in repeated cross-validation against 215 healthy individuals. Hou et al. 2024 re-implemented ten published fragmentation patterns and DELFI with one support vector machine each on the same cohort. They are independent of every pattern except IFS, which their corresponding author developed. In 10 x 10-fold cross-validation, pan-cancer AUC within open chromatin regions ranged from 0.8741 (fragment length) to 0.9736 (5' end motif), and their DELFI re-implementation reached 0.9575. Rankings changed on independent cohorts. On 46 lung cancers and 385 healthy individuals, with a model trained on 12 lung cancers, the end-motif model fell to AUC 0.5355 and sensitivity 0.0652 at 95% specificity, while fragment size distribution reached 0.9386 and 0.7174. Hou et al.'s supplementary pan-cancer and liver cancer sensitivities conflict with other tables of the same file and are not shown. Wang et al. 2026, the UNITE developers, stratified cancers by ichorCNA tumour fraction in pooled public and new 0.1x data that include samples of the DELFI and Jiang et al. cohorts used above. For cancers with an estimated tumour fraction of 3% or less, cross-validated AUC was 0.878 for all five features combined, 0.873 for fragment length, 0.857 for the SD of length counts, 0.736 for copy number, 0.715 for the C/T end-motif ratio and 0.651 for the short/long ratio, against 0.603 for a classifier using the ichorCNA tumour fraction alone, which detected 0.058 of these cancers at 95% specificity. For cancers with an estimated fraction above 3% and up to 10%, the ichorCNA classifier reached 0.983, above the combined model (0.962) and copy number alone (0.926). The extracted UNITE tables give sensitivity at a fixed specificity only for the ichorCNA comparator; the fragmentomic models' values are in a sheet not yet extracted. Jamshidi et al. 2022 (Cancer Cell), by the GRAIL developers, scored fragment length and fragment endpoint classifiers from 30x cfDNA whole-genome sequencing on the same CCGA substudy 1 participants as their methylation, copy-number and variant classifiers, at a 98% specificity threshold set post hoc within each set. On the validation set of 464 cancers and 362 non-cancers the fragment length classifier detected 29% (95% CI 25% to 34%) and the fragment endpoint classifier 18% (15% to 22%), against 34% for whole-genome methylation analysed double-blinded; both fragment classifiers were developed after the validation set had been unblinded, so these are not blinded validation results, and no tumour-fraction-stratified sensitivity is printed. Zeng et al. 2026 (Nature Cancer), by the cfMeDIP-seq developers, computed fragmentomic features from cfMeDIP-seq reads, which are enriched for methylated fragments rather than drawn from whole-genome sequencing, and report means over 10 fold models. On an independent paired-end validation set, a fragment-ratio classifier reached AUC 0.848 and detected 0.533 of cancers at 99% specificity, and fragment ratios combined with methylation reached 0.954 and 0.766. The validation set has 17 healthy controls, so its 99% specificity allows no false positive among them, and Li-Fraumeni syndrome carriers without current cancer count as cancers in its sensitivities. Three of the five classifiers that include end motifs scored below AUC 0.5 there, which the authors attribute to healthy controls processed with a different laboratory protocol, so validation results for all five are not shown. Helzer et al. 2025 (Nature Communications) compared twelve fragmentomic metrics adapted to targeted exon panels, including the authors' own fragment-size entropy metrics, their combination and Griffin, with one classifier and shared folds, on plasma from patients with metastatic cancer. The healthy-versus-cancer one-vs-rest AUROC ranged from 0.835 (open-chromatin entropy) to 0.989 (first-exon depth) in a UW cohort of 404 cancers and 27 healthy donors, with Griffin at 0.944, and from 0.951 to 1.000 in public GRAIL panel data from 151 cancers and 47 healthy donors. In a developer comparison on 0.1x whole-genome sequencing (Cell Reports Medicine 2026), a fragment-level language model (Fragmentia-AI) reached AUC 0.9561 on a held-out set of unstated size, against 0.9209 to 0.935 for the developers' re-implementation of DELFI features and 0.881 to 0.8863 for Griffin features under three classifiers. The same company's whole-genome model (Molecular Biomedicine 2026), on an independent test cohort of 2,952 cancers and 3,044 non-cancer controls, reached AUC 0.910 for cancers with an ichorCNA tumour fraction below 3% and detected 0.46 of them at a cutoff set to 98% specificity in training (observed test specificity 0.97); among those low-fraction cancers it detected 0.391 at stage I/II (637 of 1,628) and 0.708 at stage III/IV (345 of 487). Its tumour-fraction strata are ichorCNA estimates, no comparator was run on its cohorts, and its training cohort has the same number of non-cancer controls (1,245) as the Cell Reports Medicine cohort, so the two studies may share samples. Three of these four studies report on their authors' own method, and in the fourth the authors' own entropy metrics are among those compared. Cohorts, feature implementations, classifiers and validation designs differ, so no value is comparable across sources. (amp-20261007-ctdna-fragmentomics-source: result amp-20261007-ctdna-fragmentomics-result; ctdnafrag-20261009-source-hou2024: Table 1, P24 and P44; ctdnafrag-20261009-source-hou2024-supporting-information: Table S3; ctdnafrag-20261009-source-wang2026-data-file-s2: STATS_xgb_x1-x6 and STATS_lr; ctdnafrag-20261009-source-wang2026: Results and Methods; ctdnajam-20261010-source-jamshidi2022: Table 3 validation column and Results, cancer signal origin prediction; ctdnalit-20261011-zeng2026-source-article: Results P28-P33; ctdnalit-20261011-zeng2026-source-source-data-fig4: sheets Fig.4c and Fig.4d; ctdnalit-20261011-helzer2025-source-supplementary-information: Supplementary Tables S1 and S2, 'Normal' columns; ctdnalit-20261011-helzer2025-source-article: Results P5-P8; ctdnalit-20261011-fragmentia2026-source-document-s1: Table S5; ctdnalit-20261011-fragmentia2026-source-article: Results P39-P44; ctdnalit-20261011-fragmentiawgs2026-source-article: Results P8-P21; ctdnalit-20261011-fragmentiawgs2026-source-supplementary-material-1: Tables S1 and S4)
  • Evidence summary: plasma ctDNA methylation detection workflows: Summary Six bounded sources compare cfDNA methylation methods. None is a prospective screening study and none measures clinical benefit. Jamshidi et al. 2022 (Cancer Cell), by the GRAIL developers, compared prototype cfDNA classifiers on the same CCGA substudy 1 participants at a 98% specificity threshold set post hoc within each set. On the validation set of 464 cancers and 362 non-cancers, analysed double-blinded, the whole-genome bisulfite methylation classifier detected 34% of cancers (95% CI 30% to 39%; 158 of 464), against 33% for variants with white-blood-cell correction, 30% for copy number with that correction, 27% for copy number, 16% for uncorrected variants and 2.6% for clinical risk factors alone; only the gap to the corrected variant classifier was not marked as significant. Among 127 validation cancers detected by all three representative classifiers, a methylation origin classifier developed after unblinding assigned the correct tissue for 75% (95 of 127), against 41% for copy number and 35% for corrected variants, with 'other' counted as correct for six cancer types. These are case-control results from the assay developer, not screening performance. Sun et al. 2024 (Genome Biology), an independent benchmark whose authors did not develop the tools, deconvolved real plasma with five methods and reported the ROC-AUC of a random forest trained on the estimated cell-type fractions; the paper does not state how the random forest was validated, so the AUCs may be in-sample. For 24 liver cancer patients and 32 healthy individuals (WGBS), AUCs were 0.96 (CelFEER), 0.93 (CelFiE), 0.91 (MethAtlas), 0.77 (cfNOMe) and 0.72 (UXM). On cfMethyl-Seq plasma (30 to 67 patients per cancer type, each against the same 193 healthy individuals), AUCs ranged from 0.72 (UXM, lung squamous cell carcinoma) to 0.93 (CelFiE, gastric cancer), and no method was highest for every cancer type. Giuili et al. 2025, a bioRxiv preprint not yet peer reviewed, ran ten reference-based tools inside the authors' DecoNFlow pipeline on in silico mixtures of tumour tissue or cell-line reads in healthy plasma reads. CelFiE had the lowest overall median tumour-fraction limit of detection in each dataset: 0.0070 (WGBS-TT), 0.0100 (RRBS-TT) and 0.0010 (RRBS-CL). CIBERSORT and EpiDISH had overall medians of 0.1000 to 0.2500 on WGBS-TT and RRBS-TT. For five tools the RRBS-CL values disagree between the supplementary table and Figure 4A and are not shown. Nguyen et al. 2023 (eLife), by the developers of the SPOT-MAS assay at Gene Solutions, compared three tissue-of-origin classifiers on combined methylation, fragment-length, copy-number and end-motif features from cancer patients only. In the validation cohort of 239 patients, overall accuracy was 0.53 (random forest), 0.69 (deep neural network) and 0.69 (graph convolutional network); the graph network was trained with the validation samples in its graph. Zeng et al. 2026 (Nature Cancer), by the cfMeDIP-seq developers, compared a cfMeDIP-seq methylation classifier with fragmentomic features of the same reads and their combinations, reporting means over 10 fold models. In cross-validation on 356 cancers and 64 healthy donors, methylation alone reached AUC 0.986 and detected 0.949 of cancers at 99% specificity; on an independent validation set its sensitivity at 99% specificity was 0.633, against 0.766 for methylation combined with fragment ratios. These sensitivities are read on few healthy controls (six or seven per cross-validation fold and 17 in the validation set), so 99% specificity there allows no false positive among them, and Li-Fraumeni syndrome carriers without current cancer count as cancers in the validation sensitivities. The Source Data give the methylation-only validation AUC as 0.694 and the text as 0.674, so that value is not shown. Xu and Feng 2026, a medRxiv preprint not yet peer reviewed, by authors who did not develop CpGPT, fine-tuned the CpGPT methylation foundation model on public targeted bisulfite cfDNA data from 254 gastrointestinal cancers and 46 non-cancer controls and built four classical classifiers themselves. On three train/validation/test splits with test partitions of about 30 samples, mean test AUROC was 0.9904 for CpGPT against 0.9573 (SVM), 0.9420 (elastic net), 0.8460 (gradient boosting) and 0.8408 (random forest); the candidate CpGs were selected using all 300 samples, including the test partitions. Neither study reports performance in a screening population. Tissue-of-origin evidence here comes from two developer studies, one methylation-only classifier scored on already detected cancers and one multimodal workflow, and neither classifies people without cancer. (ctdnameth-20261009-source-sun2024-additional-file-1: Table S7 I4:M4, M8, J9; ctdnameth-20261009-source-sun2024: Methods P30; ctdnameth-20261009-source-giuili2025-supp-table-3: sheet B B3:D4, B7:C7; ctdnameth-20261009-source-nguyen2023-supp-file-1: Table S9 B19:E19; ctdnajam-20261010-source-jamshidi2022: Table 3 validation column and Results, cancer signal origin prediction; ctdnalit-20261011-zeng2026-source-article: Results P28-P33; ctdnalit-20261011-zeng2026-source-source-data-fig4: sheets Fig.4a-Fig.4d; ctdnalit-20261011-cpgpt2026-source-preprint: Table 3; Methods; Results)
  • headline_finding: ctdnajam-20261010-protocol-ccga1-validation-sens-98spec: Headline finding In a multivariate analysis of detection against log10(cTAF), cancer type and clinical stage, cTAF was the only significant predictor of classifier performance; without cTAF, stage became significant. cTAF accounted for 72% of the variance in WG methylation classifier scores. (Results, cTAF; Table S1 and Figure S7 (supplement not extracted))
  • observed_specificity: ctdnajam-20261010-protocol-ccga1-validation-sens-98spec: Observed specificity At the 98% target the observed specificity was 97.9% (548/560) in training and 97.8% (354/362) in validation for every cfDNA classifier; for the clinical data classifier it was 98.0% (540/551) and 97.8% (350/358), with fewer participants because of a missing clinical variable. (Table 3 footnotes a and e)
  • related_result: ctdnajam-20261010-protocol-ccga1-validation-sens-98spec: Related result Per-classifier clinical limits of detection (cTAF at 50% detection, 98% specificity) are shown only in Figure 3 and Figure S2. The text gives one value: the later targeted methylation test, on 559 solid-cancer participants of the second CCGA substudy validation set, had a clinical LOD of 1.3 x 10^-4 cTAF at 98% specificity (3.1 x 10^-4 at its reported 99.3% specificity), described as almost an order of magnitude better than the top classifiers here. That is a different assay on different samples and is not stored as a result. (Results, clinical LOD from the second CCGA substudy; Figure 3 legend)
  • Relevance of ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?": Assessed by CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation (ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods)
  • Relevance of ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec to "Which measured methylation workflow detects tumour-derived plasma DNA and, where separately supported, identifies tissue of origin?": Assessed by CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation (ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods)
  • Relevance of ctdnajam-20261010-protocol-ccga1-validation-cso-accuracy to "Which measured methylation workflow detects tumour-derived plasma DNA and, where separately supported, identifies tissue of origin?": Assessed by CCGA substudy 1 validation set: cancer signal origin accuracy among jointly detected cancers (ctdnajam-20261010-source-jamshidi2022: Results, cancer signal origin prediction; STAR Methods, CSO prediction)
  • Relevance of ctdnajam-20261010-protocol-ccga1-validation-sens-98spec to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?": Assessed by CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity (ctdnajam-20261010-source-jamshidi2022: Table 3, validation columns and footnotes)
  • Relevance of ctdnajam-20261010-protocol-ccga1-validation-sens-98spec to "Which measured methylation workflow detects tumour-derived plasma DNA and, where separately supported, identifies tissue of origin?": Assessed by CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity (ctdnajam-20261010-source-jamshidi2022: Table 3, validation columns and footnotes)

Models, benchmarks and other records

Methods (10)

Configurations (10)

Protocols (3)

Datasets (3)

Evaluations (22)

Use cases (2)

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

23 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Access and reuse
CC BY-NC-ND 4.0, printed on the first page of the article and on the figshare record.
Source metadata
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

No field-specific location recorded

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.access_and_reuse

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Archive note
Not archived in the batch: the licence forbids commercial reuse and the PDF is 2,459,162 bytes. The artifact_sha256 pins the bytes that were read; figshare's computed MD5 for the file is 6f51c7dc523d231b6c0ce268257bd3b8.
Source metadata
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

No field-specific location recorded

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.archive_note

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Artifact SHA-256
5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a
Source metadata
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

No field-specific location recorded

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_sha256

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Artifact url
https://ndownloader.figshare.com/files/38559380
Source metadata
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

No field-specific location recorded

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_url

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Doi
10.1016/j.ccell.2022.10.022
Source metadata
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

No field-specific location recorded

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.doi

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Extraction method
pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py
Source metadata
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

No field-specific location recorded

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.extraction_method

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Licence
CC-BY-NC-ND-4.0
Source metadata
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

No field-specific location recorded

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.licence

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Media type
application/pdf
Source metadata
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

No field-specific location recorded

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.media_type

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Publication status
peer_reviewed
Source metadata
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

No field-specific location recorded

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.publication_status

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Retrieval note
Not in PMC; Europe PMC has no full text or supplementary files; cell.com and ScienceDirect returned 403 and the Elsevier API returned 429. The Crick figshare deposit holds the publisher PDF of the version of record.
Source metadata
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

No field-specific location recorded

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieval_note

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

Primary source retrieved and hashed for the CCGA substudy 1 follow-up pass.

Release history

No supporting source is linked yet.

Read original source

Download this release (gzip)
Technical metadata and extraction receipts

Stable ID: ctdnajam-20261010-source-jamshidi2022

areas
dna-genomes
contexts
clinical_research
url
https://doi.org/10.1016/j.ccell.2022.10.022
artifact url
https://ndownloader.figshare.com/files/38559380
version
Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
retrieved at
2026-10-10T06:05:17Z
artifact sha256
5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a
publication status
peer_reviewed
licence
CC-BY-NC-ND-4.0
media type
application/pdf
doi
10.1016/j.ccell.2022.10.022
source locator
Full artifact bytes; per-record locators on each record
access and reuse
CC BY-NC-ND 4.0, printed on the first page of the article and on the figshare record.
archive note
Not archived in the batch: the licence forbids commercial reuse and the PDF is 2,459,162 bytes. The artifact_sha256 pins the bytes that were read; figshare's computed MD5 for the file is 6f51c7dc523d231b6c0ce268257bd3b8.
retrieval note
Not in PMC; Europe PMC has no full text or supplementary files; cell.com and ScienceDirect returned 403 and the Elsevier API returned 429. The Crick figshare deposit holds the publisher PDF of the version of record.
extraction method
pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py
scope note
Developer study: most authors are GRAIL employees with equity in Illumina, and several are inventors on related GRAIL patent applications (Declaration of interests). All classifiers were built and run by GRAIL. Samples are from CCGA (NCT02889978) substudy 1.
Related records

    Suggest a correction